Steminent Biotherapeutics Inc. (TPEX:7729)

Market Cap	5.26B +354.8%
Revenue (ttm)	n/a
Net Income	-174.04M
EPS	-2.95
Shares Out	66.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	182,927
Open	74.90
Previous Close	74.90
Day's Range	73.00 - 80.50
52-Week Range	21.50 - 95.60
Beta	0.13
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About Steminent Biotherapeutics

Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It provides Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington’s disease; tissue regeneration, such as osteoarthritis; and acute syndromes consisting acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7729

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 9, 2026

Data Sources Report a data error